Pipeline Overview

Drug Planned
Pre-clinical Phase i/ii Phase iii NDA/MAA
GI & Inflammation
RHB-105 H. pylori infections
RHB-104 Crohn's disease
Multiple sclerosis
RHB-106 Bowel cleanser
Gastroenteritis & gastritis
Oncology - GI/Inflammation
Oncology support
YELIVA™ (ABC294640) Multiple indications
MESUPRON® Solid tumors
RP101 Pancreatic cancer
*Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies ** Based on top-line results;

Company Profile

RedHill Biopharma (NASDAQ / TASE: RDHL) is an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers.

Read more

Alicia Rotbard - In Loving Memory

RedHill Board of Directors and team wish to express their deepest sadness over the passing of our very dear friend, Alicia Rotbard, a member of RedHill’s Board of Directors. Our thoughts and prayers are with her family and many loved ones. She will be greatly missed.